London Stock Exchange welcomes Indivior PLC to open trading

London Stock Exchange welcomes Indivior PLC, a global specialty pharmaceutical company committed to pioneering and delivering innovative, quality treatments for the chronic relapsing conditions and co-morbidities of addiction. With the admission to trading of its ordinary shares, Indivior marked the successful demerger of the Reckitt Benckiser Pharmaceuticals business from the Reckitt Benckiser Group plc (LON: RB) and the beginning of its operations as a fully independent and separate holding company.

Indivior is the global leader in the treatment of opioid dependence with 20 years of experience in the field and a unique patient focused approach. Indivior’s core products, which are currently available in over 40 countries, include Suboxone® Film (buprenorphine and naloxone sublingual film), Suboxone® Tablet (buprenorphine and naloxone sublingual tablets), and Subutex® Tablet (buprenorphine sublingual tablets), all of which are treatments for opioid dependence. Suboxone® Film was initially launched in the United States in 2010.  It currently maintains a share of approximately 58% in the United States market for buprenorphine-based opioid dependence treatment (based on volume of prescribed milligrams). In addition to extension candidates for its opioid dependence treatments, Indivior has a pipeline of potential new drug candidates for the treatment of opioid overdose, alcohol abuse use disorder, cocaine intoxication, and schizophrenia. The company is UK domiciled and headquartered in Richmond, Virginia in the United States.  Indivior has over 700 employees worldwide covering North America; Europe, Middle East and Africa (EMEA); Australasia; and Greater China.

On 23 December 2014, Indivior was admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the main market of the London Stock Exchange under the ticker "INDV".

Shaun Thaxter, CEO of Indivior, commented:

"This is an exciting time for Indivior, our shareholders, and most importantly, the patients and healthcare professionals we serve. We look forward to continuing, as Indivior, our dedicated efforts to transform the global addiction treatment landscape as we know it. With the breadth and depth of our pipeline, Indivior remains well positioned to drive long-term value for our shareholders while continuing to provide real-world treatment solutions to those suffering from addiction and other related mental health disorders."